• OPEN AN ACCOUNT
Indian Indices
Sensex
82,853.17 -821.75
( -0.98%)
Global Indices
Nasdaq
49,462.85 -679.56
(-1.36%)
Dow Jones
6,851.97 -110.50
(-1.59%)
Hang Seng
57,040.53 -599.31
(-1.04%)
Nikkei 225
10,413.72 -58.39
(-0.56%)
Forex
USD-INR
90.66 0.06
(0.07%)
EUR-INR
107.82 -0.02
(-0.02%)
GBP-INR
123.81 -0.01
(0.00%)
JPY-INR
0.59 0.01
(1.13%)

EQUITY - MARKET SCREENER

Ajanta Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
532331
INE031B01049
330.3875196
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJANTPHARM
38.28
36093.9
EPS(TTM)
Face Value()
Div & Yield %
75.48
2
0.97
 

datamatics global services ltd
Ashok Leyland’s January 2026 sales jump 27% YoY to 21,920 units
Feb 01,2026
The company’s total domestic sales rose 31% year-on-year to 20,079 units in January 2026.

Domestic sales of medium and heavy commercial vehicles (M&HCV) increased 30% to 12,833 units, while light commercial vehicle (LCV) sales grew 33% to 7,246 units in January 2026 compared to the same month last year.

Ashok Leyland is involved in the manufacture and sale of a broad range of commercial vehicles and also makes engines for industrial and marine applications, as well as forgings and castings.

The company reported a marginal rise in standalone net profit to Rs 771.06 crore in Q2 FY26, compared to Rs 770.10 crore posted in Q2 FY25. Revenue from operations jumped 9.34% year-on-year (YoY) to Rs 9,588.18 crore for the quarter ended 30 September 2025.

Shares of Ashok Leyland fell 3.84% to close at Rs 189.20 on the BSE.